Sasya Dronavalli

Assistant Professor

UAMS

COM | Internal Med Hem-Onc

1 h-index 10 pubs 1 cited

Research Areas

Biomedical Subjects

Links

ORCID UAMS TRI Profile

OverviewAI-generated summary

Sasya Dronavalli, Assistant Professor in the Department of Internal Medicine, Division of Hematology-Oncology at the University of Arkansas for Medical Sciences, focuses on hematologic malignancies, particularly multiple myeloma. Their recent work investigates clinical outcomes and risk factors associated with cytomegalovirus (CMV) reactivation in patients treated with teclistamab, a bispecific antibody. Dronavalli also studies the prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy for relapsed/refractory multiple myeloma, as well as real-world infectious complications and intravenous immunoglobulin (IVIG) utilization following teclistamab treatment. Further research examines the influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy. Collaborations include work with colleagues at the University of Arkansas for Medical Sciences, such as Syed Naqvi and Fenghuang Zhan.

Metrics

h-index: 1
Publications: 10
Citations: 1

Positions

University of Arkansas for Medical Sciences 2024–present

Oncology ORCID
Assistant Professor publications 2025–2026

University of Arkansas for Medical Sciences COM | Internal Med Hem-Onc Institutional directory

Selected Publications

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Blood Cancer Journal DOI OpenAlex
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 -6 . (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)

Blood DOI OpenAlex
Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation (2025)

Cureus DOI OpenAlex